• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care
Rare Disease : Episode 13

Episode 14 - Unmet Needs for Treatment of SLE


Although currently limited, Michelle Petri, MD, MPH, explains that the drug market for treating systemic lupus erythematosus (SLE) is growing. Dr Petri explains that because SLE is a heterogeneous disease that manifests in patients in many different ways, new agents to treat SLE will be classified into a series of different categories.

Dr Petri continues the discussion by exploring the future roles of these new agents which leads the panelists into a conversation about the costs of these treatment options.

Hugh Fatodu, RPh, MBA, and Dr Petri conclude that without proper data that review the long-term outcomes of agents for the treatment of SLE, it is difficult to estimate any economic benefits or advantages.

Related Videos
Landman family
Bevey Miner, executive vice president of health care strategy and policy, Consensus Cloud Solutions
Dr Jeffrey Sippel
dr kimberly maxfield
Ruben A. Mesa, MD, FACP, president and executive director of Atrium Health Levine Cancer Institute (LCI) and Atrium Health Wake Forest Baptist Comprehensive Cancer Center
Amal Trivedi, MD
Related Content
© 2023 MJH Life Sciences
All rights reserved.